Standout Papers

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic M... 1999 2026 2008 2017 3.7k
  1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (2001)
    Brian Druker, Moshe Talpaz et al. New England Journal of Medicine
  2. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome (2001)
    Brian Druker, Charles L. Sawyers et al. New England Journal of Medicine
  3. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia (2002)
    Hagop Kantarjian, Charles L. Sawyers et al. New England Journal of Medicine
  4. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias (2006)
    Moshe Talpaz, Neil P. Shah et al. New England Journal of Medicine
  5. The Biology of Chronic Myeloid Leukemia (1999)
    Stefan Faderl, Moshe Talpaz et al. New England Journal of Medicine
  6. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study (2002)
    Moshe Talpaz Blood
  7. Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer (2001)
    Michael S. Gordon, Kim Margolin et al. Journal of Clinical Oncology
  8. The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias (1988)
    Franklin H. Epstein, Razelle Kurzrock et al. New England Journal of Medicine
  9. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 (2002)
    Nicholas J. Donato, Ji Yuan Wu et al. Blood
  10. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine
  11. Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia (1986)
    Moshe Talpaz, Hagop M. Kantarjian et al. New England Journal of Medicine
  12. Clinical toxicity of interferons in cancer patients: a review. (1986)
    Jorge R. Quesada, Moshe Talpaz et al. Journal of Clinical Oncology

Immediate Impact

9 by Nobel laureates 60 from Science/Nature 170 standout
Sub-graph 1 of 17

Citing Papers

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
2017 Standout
Personalized medicine: Time for one-person trials
2015 StandoutNature
105 intermediate papers

Works of Moshe Talpaz being referenced

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
2012
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
and 110 more

Author Peers

Author Last Decade Papers Cites
Moshe Talpaz 28654 22419 12929 765 44.0k
Brian Druker 29898 21325 13369 597 54.0k
Andreas Hochhaus 29429 23691 15371 819 39.2k
Francis J. Giles 20046 15414 6250 778 41.0k
Susan O’Brien 20888 16969 5501 837 35.7k
Guillermo Garcia‐Manero 29771 14343 4360 1.5k 42.9k
Ayalew Tefferi 34157 37379 15562 1.1k 53.3k
Michele Baccarani 19737 14203 7958 704 28.3k
Srđan Verstovšek 18254 18322 8353 1.1k 29.2k
John M. Goldman 21809 13997 8428 486 29.2k
Giuseppe Saglio 18032 13149 6880 643 24.4k

All Works

Loading papers...

Rankless by CCL
2026